Top

Research Article

Split Viewer

Mol. Cells 2006; 22(3): 291-299

Published online January 1, 1970

© The Korean Society for Molecular and Cellular Biology

Vitexin, an HIF-1α Inhibitor, Has Anti-metastatic Potential in PC12 Cells

Hwa Jung Choi, Jae Soon Eun, Bang Geul Kim, Sun Yeou Kim, Hoon Jeon, Yunjo Soh

Abstract

Vitexin, a natural flavonoid compound identified as apigenin-8-C-b-D-glucopyranoside, has been reported to exhibit antioxidative and anti-inflammatory properties. In this study, we investigated its effect on hypoxia-inducible factor-1a (HIF-1a) in rat pheochromacytoma (PC12), human osteosarcoma (HOS) and human hepatoma (HepG2) cells. Vitexin inhibited HIF-1a in PC12 cells, but not in HOS or HepG2 cells. In addition, it diminished the mRNA levels of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF), smad3, aldolase A, enolase 1, and collagen type III in the PC12 cells. We found that vitexin inhibited the migration of PC12 cells as well as their invasion rates, and it also inhibited tube formation by human umbilical vein endothelium cells (HUVECs). Interestingly, vitexin inhibited the hypoxia-induced activation of c-jun N-terminal kinase (JNK), but not of extracellular-signal regulated protein kinase (ERK), implying that it acts in part via the JNK pathway. Overall, these results suggest the potential use of vitexin as a treatment for diseases such as cancer.

Keywords c-jun N-terminal Kinase; Hypoxia-inducible Factor-1α; Vascular Endothelial Growth Factor; Vitexin.

Article

Research Article

Mol. Cells 2006; 22(3): 291-299

Published online December 31, 2006

Copyright © The Korean Society for Molecular and Cellular Biology.

Vitexin, an HIF-1α Inhibitor, Has Anti-metastatic Potential in PC12 Cells

Hwa Jung Choi, Jae Soon Eun, Bang Geul Kim, Sun Yeou Kim, Hoon Jeon, Yunjo Soh

Abstract

Vitexin, a natural flavonoid compound identified as apigenin-8-C-b-D-glucopyranoside, has been reported to exhibit antioxidative and anti-inflammatory properties. In this study, we investigated its effect on hypoxia-inducible factor-1a (HIF-1a) in rat pheochromacytoma (PC12), human osteosarcoma (HOS) and human hepatoma (HepG2) cells. Vitexin inhibited HIF-1a in PC12 cells, but not in HOS or HepG2 cells. In addition, it diminished the mRNA levels of hypoxia-inducible genes such as vascular endothelial growth factor (VEGF), smad3, aldolase A, enolase 1, and collagen type III in the PC12 cells. We found that vitexin inhibited the migration of PC12 cells as well as their invasion rates, and it also inhibited tube formation by human umbilical vein endothelium cells (HUVECs). Interestingly, vitexin inhibited the hypoxia-induced activation of c-jun N-terminal kinase (JNK), but not of extracellular-signal regulated protein kinase (ERK), implying that it acts in part via the JNK pathway. Overall, these results suggest the potential use of vitexin as a treatment for diseases such as cancer.

Keywords: c-jun N-terminal Kinase, Hypoxia-inducible Factor-1α, Vascular Endothelial Growth Factor, Vitexin.

Mol. Cells
Jan 31, 2023 Vol.46 No.1, pp. 1~67
COVER PICTURE
RNAs form diverse shapes and play multiple functions as central molecules of gene expression. In this special issue on RNA, seven minireviews illustrate how basic concepts and recent RNA biology findings are transformed into new and exciting RNA therapeutics.

Share this article on

  • line
  • mail

Molecules and Cells

eISSN 0219-1032
qr-code Download